SCDM Certification Program Reaches 500 CCDMs Worldwide
MILWAUKEE – The Society for Clinical Data Management announced that is has recently certified its 500th Certified Clinical Data Manager (CCDM).
The CCDM credential is an elite mark of excellence in and commitment to clinical data management. Approximately 160 CCDMs were certified in 2009, nearly 40% of whom live outside North America.
“The CCDM designation is recognized globally as a standard for quality data management staff,” said 2010 SCDM Chair Ralph J. Russo, CCDM. “It provides the clinical research industry with a measure of expertise.”
Since its inception in 2005, the Certified Clinical Data Manager program has enhanced the quality and professionalism of CDMs worldwide. To earn the CCDM credential, candidates must first meet minimum standards of education and experience, then pass a challenging exam testing knowledge of best practices in all areas of clinical data management. Once obtained, certification must be renewed every three years by completing education activities or retaking the exam.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
